NCT04085913|UnknownEarly Phase 1FDA Drug
Exparel Injection Effect on Postoperative Opioid Usage
Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
September 30, 2019
Actual (reported)Primary Completion
June 6, 2024
Actual (reported)Study Completion
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The question proposed by this study, is one of patient outcomes. Does intraoperative injection of Exparel decrease postoperative use of opioid pain medications in patients undergoing thyroid and parathyroid surgery? The trial seeks to assess the effect that Exparel has on postoperative pain control.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 21, 2019
Actual (reported)September 11, 2019
Actual (reported)September 30, 2019
Actual (reported)June 6, 2024
Actual (reported)July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Incidence of opioid use when given Exparel intraoperatively
Utilizing pain scale daily diary, we will evaluate the incidence of opioid usage in patients that have undergone thyroid/parathyroid surgery
After surgery, patients will be monitored for two weeks, until they return for their first postoperative appointment.
Thyroid or parathyroid surgery with local injection of lidocaine and epinephrine preincision, as is current practice.
Thyroid or parathyroid surgery with local injection of bupivicaine HCL and Epinephrine preincision.
Thyroid and parathyroid surgery with local injection of lidocaine and epinephrine preincison and Exparel postincision
Preincision injection, as is current practice
Preincision injection
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordUniversity of Missouri
Columbia, Missouri, 65212, United States
Tabitha Galloway, MD
University of Missouri Department of Otolaryngology-Head and Neck Surgery
First Submitted
June 21, 2019
First Posted
September 11, 2019
Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules
Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Start
September 30, 2019
Actual (reported)Primary Completion
June 6, 2024
Actual (reported)Study Completion
July 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
July 29, 2024
Record last verified: 2024-07
There is no plan, because IPD will not be shared with other researchers.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: